Fatty liver, insulin resistance, and dyslipidemia.
Reviewartikel, 2008

After recently being recognized as a feature of the metabolic syndrome, fatty liver has evolved as a key player in the pathogenesis of dyslipidemia. Development of nonalcoholic fatty liver disease comes from an imbalance between the influx and production of fatty acids and the use of fatty acids for oxidation or secretion as very low density lipoprotein (VLDL) triglycerides. Previously, we have shown a strong relationship between increased liver fat and overproduction of large VLDL particles. We observed recently that in patients with high liver fat, insulin was unable to regulate VLDL production. The result is increased concentrations of VLDL particles in the circulation. Consequently, changes are seen in the metabolism of other lipoproteins that interact with VLDL particles, the net result being decreased high-density lipoprotein cholesterol and increased formation of small, dense low-density lipoprotein. In this article, we review recent findings on the development of fatty liver and its role in the diabetic dyslipidemia pathogenesis.

complications

Fatty Liver

metabolism

complications

Dyslipidemias

Kinetics

pathology

Liver

Lipid Metabolism

Humans

Insulin Resistance

Författare

Martin Adiels

Göteborgs universitet

Marja-Riitta Taskinen

Jan Borén

Göteborgs universitet

Current Diabetes Reports

1534-4827 (ISSN) 1539-0829 (eISSN)

Vol. 8 1 60-4

Ämneskategorier

MEDICIN OCH HÄLSOVETENSKAP

DOI

10.1007/s11892-008-0011-4

PubMed

18367000